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Abstract 
Metastatic melanoma has long been considered to have a very poor prognosis and to be chemo-resistant. However, 
a subgroup of patients with metastatic melanoma presents remarkable responses to chemotherapeutic agents, even 
in the absence of a response to modern targeted therapies and immunotherapies; accordingly, determining predic-
tive biomarkers of the response to chemotherapies for metastatic melanoma remains a priority to guide treatment 
in these patients. We report a case study of a patient with B-Raf proto-oncogene serine/threonine kinase-mutated 
metastatic melanoma harbouring many genetic mutations. The patient did not respond to prior targeted therapies 
or immunotherapies but experienced a dramatic objective radiological and clinical response to subsequent dacar-
bazine-based chemotherapy. In the era of targeted therapies and immunotherapies for metastatic melanoma, cyto-
toxic chemotherapies may still represent an interesting therapeutic weapon in a well-defined subgroup of patients 
presenting with specific genetic and molecular features.
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Background
Malignant melanoma is a malignancy with a fast grow-
ing incidence [1, 2]. Metastatic melanoma has long 
been considered to exhibit a dismal prognosis and to be 
chemo-resistant.
In the recent era of emergent targeted therapies and 
immunotherapies, metastatic melanoma is the first solid 
tumor to benefit from this therapeutic revolution and 
has become the pioneer malignancy in these therapeutic 
areas. The presence of the B-Raf proto-oncogene serine/
threonine kinase (BRAF) V600 mutation in 40%–50% of 
melanomas and its role as a predictive factor of response 
to BRAF inhibitors in combination with mitogen-acti-
vated protein kinase kinase (MEK) inhibitors were crucial 
in establishing an appropriate therapeutic management 
algorithm for metastatic melanomas [3].
Although melanoma has long been considered to be 
chemo-resistant, cytotoxic chemotherapy represented 
the only available therapeutic option for metastatic mela-
noma before the era of targeted therapies and immuno-
therapies. Many chemotherapy regimens only induced 
modest response rates; the most common regimens were 
dacarbazine-based and induced objective response rates 
(ORRs) ranging from 15% to 20% [4]. An observational 
study has indicated prolonged remission for 7 years [5]. 
The combination of dacarbazine with other agents, espe-
cially cisplatin, produced better results than dacarbazine 
alone in terms of ORR and progression-free survival but 
not overall survival [6].
Currently, in BRAF V600-mutated metastatic mela-
noma, the combination of BRAF and MEK inhibitors 
is considered the standard of care, with response rates 
exceeding 70% for first-line treatment [7]. In BRAF 
non-mutated metastatic melanoma, immune check-
point inhibitors have been the standard of care since the 
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approval of ipilimumab in March 2011 [8], pembroli-
zumab in September 2014 [9], and nivolumab in Decem-
ber 2014 as first-line therapies [10]. More recently, the 
combination of nivolumab and ipilimumab (October 
2015) has shown an ORR exceeding 75%, a gain accom-
panied by higher and more pronounced toxicities than 
those observed in single-agent immunotherapy trials 
[11].
In this paper, we report a case of a patient with BRAF-
mutated metastatic melanoma harbouring many genetic 
mutations who did not respond to targeted therapies 
(BRAF and MEK inhibitors) or to immune checkpoint 
inhibitors, such as ipilimumab and nivolumab, but pre-
sented an impressive and dramatic response to subse-
quent cytotoxic chemotherapy consisting of dacarbazine 
and cisplatin. We also discuss the potential role of chem-
otherapy after BRAF and MEK inhibitor treatment and 
immunotherapy as well as the potential interest and ben-
efit of chemotherapy in particular subgroups of patients.
Case report
A 56-year-old man with a history of hypercholester-
olemia and myocardial infarction presented in December 
2013 with a dermatologic lesion in the left lumbar region. 
The pathologic examination of the excisional biopsy 
revealed an ulcerated malignant melanoma of 6.5 mm in 
thickness (Breslow). The type was a superficial spreading 
melanoma, and the Clark level was 4.
After a wide excision of the lesion with 2  cm mar-
gins, the pathologic results of the sentinel lymph nodes 
showed an invasion of malignant melanoma, requiring a 
subsequent complete left inguinal lymph node dissection. 
The pathologic TNM stage was pT4bpN1acM0 according 
to the 7th edition of the American Joint Committee on 
Cancer/Union for International Cancer Control (AJCC/
UICC) staging system. The primary tumor exhibited the 
typical BRAF V600E mutation.
Four months later, in April 2014, the patient presented 
a locoregional cutaneous and subcutaneous relapse in 
the lumbar region. First-line treatment consisted of the 
single-agent BRAF inhibitor vemurafenib, which had to 
be stopped, despite a clinical response, due to unaccep-
table toxicities, such as a grade 4 skin rash and a grade 
2 daily fever. A shift to dabrafenib in combination with 
trametinib in a medical need programme was initiated 
in July 2014 and stopped in December 2014 after clinical 
progression of the lumbar local relapse and of multiple 
in-transit metastases.
Between January and March 2015, the patient received 
4 injections of ipilimumab, a monoclonal anti-cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) antibody. 
The main adverse effect after the fourth injection was 
excessive fatigue, which was attributed to auto-immune 
hypophysitis with adrenal and gonadal insufficien-
cies requiring hormonal substitution of hydrocortisone 
and topic testosterone, respectively. After 4 doses of 
ipilimumab, positron emission tomography/computed 
tomography (PET/CT) unfortunately showed progres-
sive disease and the appearance of lung and lymph node 
metastases.
Starting in July 2015, the patient was treated with 
nivolumab (twice every week), a monoclonal anti-
programmed cell death 1 (PD-1) antibody, within the 
framework of a phase II trial. A CT scan performed after 
8 weeks of nivolumab treatment demonstrated clear dis-
ease progression, including cutaneous and subcutaneous, 
lymph node, pleuro-pulmonary, renal, and peritoneal 
metastases (Fig. 1a, b). At this point, biological analyses 
indicated elevated serum lactate dehydrogenase (LDH) 
levels.
Two molecular analyses of the tumor, one using 
OncoDeep (OncoDNA, Gosselies, Belgium) and the 
other using the TruSeq Illumina Cancer Panel (Illu-
mina Inc., San Diego, CA, USA), were performed after 
the failure of nivolumab (at the end of August 2015). 
The results were discordant: the OncoDNA detected 
only one BRAF V600E mutation, whereas the Illu-
mina Panel (TruSeq Amplicon Cancer Panel) detected 
BRAF V600E-F-box and WD repeat domain containing 
7 R385C mutations (FBXW7), a kinase domain insert 
receptor Q472H variant (KDR), a V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homologue G12D mutation 
(KRAS), a tumor protein P53 P72R variant (P53), and a 
polymorphism of Ataxia telangiectasia mutated (ATM) 
−c.8850 + 60A > G.
Since September 2015, the patient had received 4 
cycles of cytotoxic chemotherapy consisting of intra-
venous injections of dacarbazine (350  mg/m2) and cis-
platin (25  mg/m2) for 3 consecutive days, given every 
3–4  weeks. An ongoing, impressive, and dramatic 
response of all metastases (the sizes decreased by more 
than 80%) was documented after 3 cycles of chemother-
apy (Fig. 1c, d).
During chemotherapy, a second biopsy was performed, 
and the same mutations were detected, but there was a 
difference in the percentage of cells with the BRAF V600E 
mutation (41% in August 2015 and 36% in November 
2015).
After the failure of checkpoint inhibitors, an immu-
nological biomarker and microenvironment analysis 
revealed the absence of PD-1/programmed death-ligand 
1 (PD-L1) (Ventana biomarker assay) staining, the 
absence of CD20 (B cells) staining, and diffuse and weak 
CD3 (T cells) staining.
We summarized the treatment provided to this patient 
in a flow chart (Fig. 2).
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Discussion
The particular clinical feature of our case was the pres-
ence of multiple genetic mutations in the tumor, which 
did not respond to targeted therapies or checkpoint 
inhibitors but exhibited a major response to dacarbazine 
and cisplatin combination chemotherapy in fifth-line 
therapy.
Apart from the differences (e.g., depth of coverage, 
number of genes analyzed, and devices and analysis sys-
tems) between the OncoDeep test and Illumina panel, 
Fig. 1 Computed tomography (CT) and macroscopic images of the inguinal lesion before and after 3 cycles of chemotherapy. a CT scan shows 
a subcutaneous metastatic melanoma lesion (arrow) of 76 mm × 63 mm in the left inguinal area before chemotherapy. b Cutaneous metastatic 
melanoma lesions (arrow) were nodular and inflammatory before chemotherapy. c CT scan shows that the size of the subcutaneous metastatic 
melanoma lesion (arrow) decreased to 31 mm × 35 mm, with a reduction of 48%, after 3 cycles of chemotherapy. d Cutaneous metastatic mela-
noma lesions (arrow) exhibited massive shrinkage, leaving a fibrotic quality of the skin, after 3 cycles of chemotherapy
Fig. 2 Flow chart summarizing the treatment provided to this patient
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the discordant results (i.e., the greater number of muta-
tions detected using the Illumina panel) may be explained 
by tumor heterogeneity due to the different origins of the 
two samples.
This rare case raises a number of questions. Is there a 
subgroup of metastatic melanomas that still benefit from 
cytotoxic chemotherapy? Are there any predictive fac-
tors leading to this response? Should the presence of the 
observed genetic mutations in metastatic melanoma be 
considered a predictive factor for chemo-sensitivity? Is 
there a potential role for immune checkpoint inhibitors 
that render these tumors more chemo-sensitive by modi-
fying the microenvironment?
Many hypotheses can be considered with respect to 
these questions. The first and strongest hypothesis is that 
the observed response is explained by the presence of an 
ATM mutation in this tumor. The ATM gene is respon-
sible for the repair of DNA double-strand breaks [12]. 
The presence of an ATM mutation leads to a dysfunc-
tion in the repair process for DNA double-strand breaks 
and consequently could render the tumor more chemo-
sensitive, especially to platinum agents, according to the 
literature [13, 14]. This process is comparable to breast 
cancer 1 gene (BRCA1)-mutated breast cancer, which 
exhibits acceptable sensitivity to platinum agents and/
or poly(ADP-ribose) polymerase (PARP) inhibitors. By 
extrapolation, the use of PARP inhibitors could be con-
sidered an interesting therapeutic modality in the pro-
gression of chemotherapy.
A second hypothesis may be the “terra incognita” effect 
of immunotherapy (anti-CTLA4 and anti-PD-1) on the 
subsequent response to chemotherapy. Cytotoxic agents 
seem to enhance the anti-tumor immune response by 
releasing antigens after cellular destruction [15, 16]. 
Some basic researches on immunological biomarkers 
and microenvironments, e.g., studies of intratumoral 
lymphoid infiltrates with intratumoral PD-L1 expression 
and the interferon-gamma pathway in tumor tissue, show 
that these factors can predict the response to immune 
checkpoint inhibitors [17, 18]. In fact, high expression 
of PD-L1 and the presence of tumor-infiltrating lympho-
cytes are associated with better responses to checkpoint 
inhibitors [19, 20].
Finally, to answer these questions, a retrospective 
mutation-based study could be used to evaluate the 
response rate of metastatic melanomas to different thera-
peutic modalities according to each individual muta-
tion. Based on the results of this observational study, a 
randomized trial aimed at comparing chemotherapy to 
targeted therapies and checkpoint inhibitors based on 
different mutation profiles should be launched. A similar 
methodology will be used to confirm or clarify the sus-
tained role of chemotherapy in well-defined subgroups of 
patients, despite the encouraging and promising results 
of targeted therapies and/or immunotherapies.
Conclusions
We are currently in an exciting era of promising new 
treatment options for malignant melanoma. Cyto-
toxic chemotherapy (especially dacarbazine and 
cisplatin) could nevertheless remain an invaluable thera-
peutic weapon in specific cases with chemosensitizing 
mutations.
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